Viking Therapeutics CMO files initial Form 3

Viking Therapeutics, Inc. filed an initial ownership report for Chief Medical Officer Chen Hubert C on Form 3.

Rhea-AI Filing Summary

Viking Therapeutics, Inc. filed an initial ownership report for Chief Medical Officer Chen Hubert C on Form 3. The filing lists him as an officer but shows no reported transactions, meaning it simply establishes his status as an insider for future ownership and trading disclosures.

Key Terms

Chief Medical Officer, reportingPersons, derivativeTransactionCount

3 terms

Chief Medical Officer financial

"officer_title": "Chief Medical Officer""

A chief medical officer is a senior executive responsible for overseeing the health and medical strategies within an organization, often in the healthcare or pharmaceutical sectors. They play a key role in guiding decisions related to medical research, product safety, and healthcare policies, which can impact a company's reputation and success. For investors, understanding the chief medical officer's role helps gauge how well a company manages medical risks and advances its healthcare goals.

reportingPersons regulatory

""reportingPersons": [ { "name": "Chen Hubert C""

derivativeTransactionCount regulatory

""derivativeTransactionCount": 0"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What does the Viking Therapeutics (VKTX) Form 3 filing for Chen Hubert C mean?

The Form 3 filing shows that Chief Medical Officer Chen Hubert C is now an insider of Viking Therapeutics. It is an initial ownership report and, in this case, contains no transactions or share movements, simply establishing his reporting status going forward.

Did Viking Therapeutics (VKTX) Chief Medical Officer Chen Hubert C buy or sell shares in this Form 3?

No, the Form 3 for Chief Medical Officer Chen Hubert C reports no transactions. All transaction-related counts, including buys, sells, exercises, gifts, and tax withholding, are zero, indicating this filing only records insider status without any share activity.

What role does Chen Hubert C hold at Viking Therapeutics (VKTX) in this Form 3?

The filing identifies Chen Hubert C as an officer of Viking Therapeutics with the title Chief Medical Officer. This designation classifies him as an insider whose future holdings and trades in company securities must be reported under SEC rules.

Does the Viking Therapeutics (VKTX) Form 3 show any derivative securities for Chen Hubert C?

No, the Form 3 lists no derivative securities for Chen Hubert C. The derivativeSummary section is empty and derivativeTransactionCount is zero, indicating there are no options, warrants, or similar instruments reported for him in this initial ownership statement.

How significant is the Viking Therapeutics (VKTX) Form 3 filed for its Chief Medical Officer?

This Form 3 is largely administrative, formally identifying the Chief Medical Officer as an insider. With no transactions or positions detailed in the transaction and derivative summaries, it does not change the company’s financial picture but prepares for future required disclosures.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding Insider Trading Forms →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 06/03/2026 - 07:43 PM EDT Learn about SEC filing dates

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0104
Estimated average burden
hours per response:			0.5

1. Name and Address of Reporting Person^*

Chen Hubert C

(Last) (First) (Middle)

9920 PACIFIC HEIGHTS BLVD

SUITE 500

(Street)

SAN DIEGO CALIFORNIA 92121

(City) (State) (Zip)

UNITED STATES

(Country)

2. Date of Event Requiring Statement (Month/Day/Year)
06/01/2026

3. Issuer Name and Ticker or Trading Symbol
Viking Therapeutics, Inc. [ VKTX ]

3a. Foreign Trading Symbol

5. If Amendment, Date of Original Filed (Month/Day/Year)

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Medical Officer

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

No securities are beneficially owned.

	/s/ Michael Morneau, as Attorney-in-Fact	06/03/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 3: SEC 1473 (03-26)